0001140361-22-028097.txt : 20220803
0001140361-22-028097.hdr.sgml : 20220803
20220803200126
ACCESSION NUMBER: 0001140361-22-028097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220801
FILED AS OF DATE: 20220803
DATE AS OF CHANGE: 20220803
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wexler William A.
CENTRAL INDEX KEY: 0001927975
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11460
FILM NUMBER: 221134198
MAIL ADDRESS:
STREET 1: 12 GILL STREET
STREET 2: SUITE 4650
CITY: WOBURN
STATE: MA
ZIP: 01801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc.
CENTRAL INDEX KEY: 0000748592
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 311103425
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
BUSINESS PHONE: (212) 582-1199
MAIL ADDRESS:
STREET 1: 140 58TH STREET, BUILDING A
STREET 2: SUITE 2100
CITY: BROOKLYN
STATE: NY
ZIP: 11220
FORMER COMPANY:
FORMER CONFORMED NAME: NTN BUZZTIME INC
DATE OF NAME CHANGE: 20051230
FORMER COMPANY:
FORMER CONFORMED NAME: NTN COMMUNICATIONS INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: ALROY INDUSTRIES INC
DATE OF NAME CHANGE: 19850411
4
1
form4.xml
FORM 4
X0306
4
2022-08-01
0000748592
Brooklyn ImmunoTherapeutics, Inc.
BTX
0001927975
Wexler William A.
C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.
10355 SCIENCE CENTER DRIVE, SUITE 150
SAN DIEGO
CA
92121
true
Stock Option (right to buy)
0.49
2022-08-01
4
A
0
152100
0
A
2032-08-01
Common Stock, par value $0.005 per share
152100
152100
D
Stock Option (right to buy)
0.49
2022-08-01
4
A
0
165800
0
A
2032-08-01
Common Stock, par value $0.005 per share
165800
165800
D
The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.
The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.
/s/ William Wexler
2022-08-03